Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year
Executive Summary
Sanofi tells investors to expect further Consumer Healthcare brand divestments in 2019 as it continues to rationalize its portfolio following the transformational acquisition of Boehringer Ingelheim's OTC business in 2017. As a result of divestments in 2018, as well as a number of seasonal factors, Sanofi reported a 0.6% rise in Consumer Healthcare's sales in Q1.
You may also be interested in...
Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark
Sanofi's push to concentrate its Consumer Healthcare portfolio on priority categories sees it offload two OTC brands in Germany and Austria. Meanwhile, new Sanofi CEO Paul Hudson has spoken about his intention to review the firm's plans in the OTC market.
Sanofi Licenses OTC Tamiflu From Roche To Attempt First US Flu Treatment Switch
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.
Sanofi Partners With Colombian Tech Firm Rappi To 'Transform' Healthcare In Latin America
Sanofi Consumer Healthcare is utilizing emerging digital technology to take a bigger slice of the Latin American OTC market. Through a partnership deal, e-commerce and delivery firm Rappi will promote and sell Sanofi's brands to consumers across seven Latin American markets.